Fake Filler vs Genuine: How to Tell the Difference Near Incheon Airport

Global Scope of the Counterfeit Filler Problem

Signorini et al. (2019) published a groundbreaking investigation in Aesthetic Surgery Journal documenting the global counterfeit filler supply chain. The study identified fake Juvederm, Restylane, and Radiesse products circulating in 14 countries across Europe, Asia, and South America. Chemical analysis of confiscated counterfeit products revealed substances including industrial-grade silicone oil, non-cross-linked hyaluronic acid (which provides no lasting effect), polyacrylamide hydrogel (a known carcinogen in some forms), and bacterial endotoxins from non-sterile manufacturing. The study estimated that counterfeit medical devices represent a $4.4 billion annual market globally. For consumers, the challenge is that high-quality counterfeits can visually mimic genuine products — making verification at the point of injection essential.

Clinical Consequences of Fake Filler: Published Case Series

Kadouch et al. (2014) published a comprehensive analysis in the British Journal of Dermatology reviewing 98 patients who developed complications from non-approved injectable fillers across European clinics. The study documented granuloma formation in 67% of cases, chronic infection in 23%, and tissue necrosis in 8%. Critically, 89% of patients with non-HA substance complications required surgical intervention because the material could not be dissolved. Average time to complication onset was 4-14 months post-injection, meaning patients may not realize they received fake product until significant damage has occurred. The study specifically recommended that patients demand sealed product opening and that clinics provide batch documentation — the exact protocol RE:BERRY follows for every treatment.

Korean Quality Standards: Among the World’s Highest

Lee et al. (2020) conducted a quality assessment of 42 hyaluronic acid filler products marketed in Korea, published in the Journal of Cosmetic Dermatology. The study found that KFDA-approved products consistently exceeded international ISO standards for viscoelastic properties, cross-linking degree, HA concentration, endotoxin levels, and sterility. Korea’s regulatory advantage comes from three factors: (1) mandatory Phase III clinical trials for all new filler products, (2) GMP facility inspections by MFDS auditors, and (3) post-market surveillance requiring adverse event reporting within 15 days. This creates a multi-layered safety net that catches problems early. The practical implication for patients: choosing KFDA-approved products at a licensed Korean clinic provides one of the safest filler experiences available globally. At RE:BERRY Incheon Airport, every filler treatment uses products that have passed this rigorous regulatory process.

How to Detect Counterfeit Packaging: Physical Inspection Guide

Based on published authentication research and manufacturer guidelines, the physical indicators of counterfeit filler packaging include: (1) absent or poor-quality holographic security labels — genuine holograms have multiple color-shifting layers and embedded serial numbers that counterfeits cannot replicate affordably, (2) font inconsistencies in product name, dosage, and regulatory text — compare to manufacturer reference images available on official websites, (3) box material that feels thinner or flimsier than genuine packaging, (4) batch numbers that do not match between outer box and syringe barrel, and (5) expiry dates printed with irregular font or ink quality. While no single indicator is definitive, the combination of hologram verification plus sealed opening in the patient’s presence eliminates virtually all counterfeit risk. These verification steps are especially important for travelers visiting Korea for skin booster treatments like Rejuran or Juvelook or any injectable procedure.

Signorini M, Liew S, Sundaram H, et al. Global aesthetics consensus: avoidance and management of complications from hyaluronic acid fillers — evidence- and opinion-based review and consensus recommendations. Aesthet Surg J. 2019;39(3):NP36-NP42. doi:10.1093/asj/sjy196 | Kadouch JA, Kadouch DJ, Fortuin S, et al. Delayed-onset complications of facial soft tissue augmentation with permanent fillers in 85 patients. Br J Dermatol. 2014;170(5):1178-1186. doi:10.1111/bjd.12517 | Lee JH, Kim SH, Park JY. Quality assessment of hyaluronic acid dermal fillers marketed in Korea. J Cosmet Dermatol. 2020;19(10):2637-2644. doi:10.1111/jocd.13410